An Open-label, Prospective, Non-Comparative Study to Evaluate Subjective Well-Being and Responses in Patients With Schizophrenia Who Had Switched to Paliperidone Extended-Release Tablets
Phase of Trial: Phase IV
Latest Information Update: 23 May 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms POWER
- Sponsors Janssen
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2012 Actual patient number changed from 234 to 289 as reported by ClinicalTrials.gov.
- 10 Jan 2012 Actual end date Jan 2011 added as reported by ClinicalTrials.gov.